Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial

What Was Tested

This randomized controlled trial paper looks at Orforglipron (Foundayo, non-peptide).

This study aimed to assess orforglipron as add-on treatment to diet and exercise alone or to oral antihyperglycaemic medications in Japanese participants with type 2 diabetes.

Why It Was Studied

Orforglipron, an oral GLP-1 receptor agonist, requires further evaluation in east Asian populations with type 2 diabetes, given this group's distinct pathophysiological characteristics.

For the Japanese translation of the abstract see Supplementary Materials section.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

Investigators, participants, and site staff were not masked to treatment.

How the Study Was Run

The researchers set it up as a randomized, open-label and multicenter study.

Because people in this Orforglipron (Foundayo, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Being open-label, the Orforglipron (Foundayo, non-peptide) study did not mask who received what.

More than one site took part, so the participants came from several places.

This multicentre, randomised, open-label phase 3 study was conducted in 40 medical research centres and hospitals in Japan.

This study is registered with ClinicalTrials.gov, NCT06010004 (ACHIEVE-J).

What Was Measured

Orforglipron, an oral GLP-1 receptor agonist, requires further evaluation in east Asian populations with type 2 diabetes, given this group's distinct pathophysiological characteristics.

PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Japan, Fluorine Compounds, Oxadiazoles and East Asian People.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Orforglipron (Foundayo, non-peptide).

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (The lancet. Diabetes & endocrinology), a journal based in England.

More context: the Orforglipron (Foundayo, non-peptide) compound page, all human trials.